Maps

MAPS, Eight Capital And Integrated V.C. Backs Numinus $6M Offering
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
This Psychedelics Co. May IPO With '$100M In Revenue,' Changing Mental Health Forever, Says VC Investor
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
This Psychedelics Co. May IPO With '$100M In Revenue,' Changing Mental Health Forever, Says VC Investor
The Road To Legal Psychedelics: Is Cannabis A Good Comparison?
Jaden Smith On The Power Of Psychedelics: 'Nature Has So Many Of The Keys And Secrets We're Looking For'

Maps Recent News

MDMA Assisted Therapy Approval And Commercialization Projected Within Calendar 2024 Timeline
As the Psychedelic Science 2023 Conference in Denver wears on, interesting tidbits of data are emerging into the public sphere.
Numinus Partners With MAPS To Conduct Phase 1 MDMA Assisted Therapy Investigational Study
In a prelude to what is hoped will be regulatory approval of MDMA-assisted therapy in the U.S. and Canada, Numinus Wellness Inc. (OTC: NUMIF) has taken steps to get out in front of the curve.
Breaking Down Barriers In Psychedelic Exploration With New Video Series And Poetry
PSYC Corporation (OTC Pink Market: PSYC), a multimedia leader in psychedelics, announced the premiere of its new video series, "PSYC Taboo," which will focus on carefully selected topics highlighting the integration of psychedelics into the lives of everyday people.
EXCLUSIVE: Human Connection Is Essential Element For Healing With Psychedelics
“We are not going to be walking into a dispensary and buying DMT or ayahuasca any time soon,” said Simeon Schnapper, managing partner JLS FUND at 
This Psychiatrist Says Cannabis Is A Minor-League Psychedelic & Undervalued Investment Opportunity
Cannabis is a psychedelic that belongs to the group of mind-manifesting substances, according to Dr. Julie Holland. "When you get high on cannabis, you can see your thoughts differently, and it can give you a bigger perspective on life," she said in an interview with Rena Sherbill from the Cannabis Investing Podcast.
EXCLUSIVE: MAPS To Host Major Psychedelics Event In 2023, Speakers & Details Below
The Multidisciplinary Association for Psychedelic Studies (MAPS) has shared details for its Psychedelic Science 2023 event taking place next June 19 to 23 in Denver, Colorado. 
Country Music Joins Psychedelics Research Effort With Daniel Donato's Cosmic Tour
The art world is moving closer to endorsing psychedelics research as witnessed by Nashville-born Daniel Donato’s U.S. concert tour VIP ticket donations.
Why Magic Mushrooms Are Emerging As Major Part Of Public Discourse: How Are They Commercialized?
(Part four of a four-part series)
Drugs, Law & Federal Penalties: U.S. Sentencing Commission Finally Reaches Quorum And Resumes Late Activities
The United States Sentencing Commission (USSC), which establishes and advises Congress on federal sentencing guidelines, has reached a full panel enrollment for the first time since 2014 and, more importantly, a quorum for the first time in three years, which will allow the group to finally follow its mandate goal. 
Canada: MDMA-Assisted Therapy Trials Reviewed By Health Canada, Here's What's Happening
Health Canada has just completed a review of all active MDMA-assisted psychotherapy trials, in response to alleged patient safety issues and research flaws. The issues had resulted in one of the two existing studies being suspended while the other allowed to proceed with some "corrective and preventive" changes.
MAPS Launches Online Course Providing 'Accurate, Evidence-based Information On Psychedelics'
MAPS, an NGO leading research in the psychedelics space, is launching “Psychedelic Fundamentals,” an online psychedelic education program providing "accurate, evidence-based information on psychedelics," now available for purchase on the organization's website.
Psychedelic Art Auction: Over $1.5M Raised At Christie's Curated NFT Sale For MAPS
Cartography of the Mind has raised over $1.5 million.
Michael Pollan's 'How To Change Your Mind' Coming Soon To Netflix: Documentary Based On Psychedelics Best Seller
The freshest news traversing many of the major institutions, researchers' and activists’ accounts on Twitter is the recent release of a docu-series based on writer Michael Pollan’s 2018 book “How To Change Your Mind: What the science of psychedelics teaches us about consciousness, dying, addiction, depression, and transcendence.”
BREAKING: NFT Buyers, You Can Now Engage In Psychedelics' Legal Struggle At Christie's Auction To Support MAPS
Christie’s, the legendary art and luxury auction house, along with Dialectic and Vine Ventures, will auction off NFT works for those interested in digital art and supporting scientific studies.
Ecstasy Research Trial Completes Enrollment, Moves Closer To Approval To Treat PTSD
The non-profit Multidisciplinary Association for Psychedelics Studies (MAPS) and its subsidiary MAPS Public Benefit Corporation finished the enrollment stage for the second Phase 3 clinical trial on MDMA (MAPP2).
EXCLUSIVE: Catalysts To Watch For In The Psychedelic Space
Any biotech investor knows how important catalysts are for the companies in the space. One FDA approval or denial can make or break the price of the stock.  In the psychedelic space, catalysts could be even more important, as the industry as a whole is still in its infancy. 
DEA Under Fire For Blocking Psilocybin As Treatment For Terminally Ill Cancer Patients
The Drug Enforcement Administration (DEA) will face activists at its headquarters in Arlington, Virginia, reported Mary-Elizabeth Gifford and Justin Grant of Lucid News. Protestors intend to block the entrance to the building to call attention to the rights
These 3 Psychedelic Stocks Will Benefit When The FDA Green-Lights MDMA (Molly, Ecstasy)
What Happened: According to the Multidisciplinary Association of Psychedelic Studies (MAPS), a non-profit organization, the FDA is close to greenlighting MDMA as a treatment for PTSD. MAPS reported positive results from a phase-3 trial testing the efficacy of MDMA-assisted therapy.
Former Moderna Vice President Joins Psychedelics Company In Phase 3 Trials For Ecstasy
UK's Top Health Agency Grants "Innovation Passport" To Psychedelic Drug MDMA In Treatment Of PTSD
The UK’s Medicines and Healthcare Products Regulatory Agency has granted an “Innovation Passport” to the drug MDMA, also known as “ecstasy” or “molly,” in the treatment of post-traumatic stress disorder.
Novamind Partners With Bienstar Wellness, Opening Door To Ibogaine Treatment For Addiction Disorders
Novamind Inc. (OTCQB: NVMDF) a mental health company specializing in psychedelic medicine, recently announced a strategic investment and advisory agreement with Bienstar Wellness Corp, an Uruguay-based mental health company, to assist in the expansion of Latin Ameri
Michigan Report: $20M In Cannabis Cash To Research PTSD Among Veterans And Using Weed Does Not Disqualify Unemployment Eligibility
The state of Michigan is funding two major medical cannabis research projects to the tune of $20 million with tax revenue from the state’s recreational marijuana program, announced Michigan’s Marijuana Regulatory Agency (MRA).
Psychedelic Therapy Execs On Latest Developments In Space, Remaining Hurdles
Assisted psychedelic treatment executives came together at the two-day, virtual Benzinga Global Small Cap Conference on Thursday to discuss recent lab developments and the significant hurdles ahead in mental health and addiction treatment.